Green Journals

International Approved Journals

Journal Information

Journal Title	HIV Clinical Trials
Publisher	Taylor & Francis
ISSN	1528-4336
E-ISSN	
Database	SCOPUS
Domain	Health Sciences, Life Sciences, Social Sciences

Classification History

Year	A+	A	B	C
2026				
2025				
2024				
2023				
2021/2022				
2020				
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry
2018-11-2 Vol. 19 Issue 6 Pages 225-234
Authors: Jenny Bischoff, Stefan Mauss, Christiane Cordes et al.
DOI: 10.1080/15284336.2018.1538193

Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial
2018-11-2 Vol. 19 Issue 6 Pages 209-224
Authors: Risa M. Hoffman, Konstantia Nadia Angelidou, Sean S. Brummel et al.
DOI: 10.1080/15284336.2018.1537327

Participant characteristics and clinical trial decision-making factors in AIDS malignancy consortium treatment trials for HIV-infected persons with cancer (AMC #S006)
2018-11-2 Vol. 19 Issue 6 Pages 235-241
Authors: Jack E. Burkhalter, David M. Aboulafia, Maria Botello-Harbaum et al.
DOI: 10.1080/15284336.2018.1537349

Durability of dolutegravir plus boosted darunavir as salvage or simplification of salvage regimens in HIV-1 infected, highly treatment-experienced subjects
2018-11-2 Vol. 19 Issue 6 Pages 242-248
Authors: Amedeo F. Capetti, Giuseppe V. De Socio, Maria V. Cossu et al.
DOI: 10.1080/15284336.2018.1550290

Natural control of HIV infection in young women in South Africa: HPTN 068

2018-9-3 Vol. 19 Issue 5 Pages 202-208
Authors: Mariya V. Sivay, Jessica M. Fogel, Jing Wang et al.
DOI: 10.1080/15284336.2018.1531534

Red blood cell distribution width as an easily measurable biomarker of persistent inflammation and T cell dysregulation in antiretrovirally treated HIV-infected adults

2018-9-3 Vol. 19 Issue 5 Pages 172-176
Authors: Zao Zhang, Glen M. Chew, Cecilia M. Shikuma et al.
DOI: 10.1080/15284336.2018.1514821

Bone mass preservation with high-dose cholecalciferol and dietary calcium in HIV patients following antiretroviral therapy. Is it possible?

2018-9-3 Vol. 19 Issue 5 Pages 188-196
Authors: Quirico Mela, Valeria Ruggiero, Lorenza Montaldo et al.
DOI: 10.1080/15284336.2018.1525841

Association of raltegravir use with long-term health outcomes in HIV-infected patients: an observational post-licensure safety study in a large integrated healthcare system

2018-9-3 Vol. 19 Issue 5 Pages 177-187
Authors: Michael A. Horberg, Allison H. Oakes, Leo B. Hurley et al.
DOI: 10.1080/15284336.2018.1523826

Maximizing participant retention in a phase 2B HIV prevention trial in Kampala, Uganda: The MTN-003 (VOICE) Study

2018-9-3 Vol. 19 Issue 5 Pages 165-171
Authors: Joshua Wynne, Rosemary Muwawu, Michael C Mubiru et al.
DOI: 10.1080/15284336.2018.1513711

Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy

2018-9-3 Vol. 19 Issue 5 Pages 197-201
Authors: Álvaro Mena, Purificación Cid, Carlos Dueñas et al.
DOI: 10.1080/15284336.2018.1513974